News Column

CTI BioPharma Reports Second Quarter 2014 Financial Results

August 18, 2014

By a News Reporter-Staff News Editor at Clinical Trials Week -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) reported financial results for the second quarter and six months ended June 30, 2014 (see also CTI BioPharma Corp.).

"In July 2014, we achieved a significant milestone with the completion of enrollment in the PERSIST-1 clinical trial, the first of two Phase 3 trials of our oral tyrosine kinase inhibitor that has dual activity against JAK2 and FLT3 for patients with myelofibrosis," said James A. Bianco, M.D., President and CEO. "We look forward to reporting top-line results from this first Phase 3 trial in early 2015, while also advancing our second Phase 3 trial for pacritinib; driving E.U. sales of PIXUVRI(®) for relapsed aggressive B-cell NHL and advancing Phase 2 studies of pacritinib and tosedostat in other hematologic malignancies."

Select Second Quarter 2014 and Recent Highlights

Keywords for this news article include: CTI BioPharma Corp., Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Clinical Trials Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters